Day: November 12, 2024

Third Quarter Highlights Revenue of $35.4 million, decrease of 5.6% year-over-year and increase of 5.5% sequentially Gross margin increased to 32.6%, a 800 bps increase year-over-year and 1,300 bps increase sequentially Operating profit of $2.5 million, an increase of $2.2 million year-over-year and $3.8 million sequentially Net loss of $2.8 million includes $0.7 million of FX losses, a decrease of $0.1 million year-over-year and $2.0 million sequentially Adjusted EBITDA from continuing operations of $4.8 million, an increase of $2.6 million year-over-year and $3.6 million sequentially Announced plans to divest on-demand printing operation LONDON and SANTA MONICA, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) — XBP Europe Holdings, Inc. (“XBP Europe” or “the Company”) (NASDAQ: XBP), a pan-European integrator of bills, payments, and...

OTTAWA, Ill., Nov. 12, 2024 (GLOBE NEWSWIRE) — Ottawa Bancorp, Inc. (the “Company”) (OTCQX: OTTW), the holding company for OSB Community Bank (the “Bank”), announced net income of $0.2 million, or $0.08 per basic and diluted common share for the three months ended September 30, 2024, compared to net income of $0.5 million, or $0.20 per basic and diluted common share for the three months ended September 30, 2023. For the nine months ended September 30, 2024, the Company announced net income of $0.3 million, or $0.10 per basic and diluted common share, compared to net income of $1.5 million, or $0.58 per basic and diluted common share for the nine months ended September 30, 2023. The loan portfolio, net of allowance, decreased to $304.2 million as of September 30, 2024 from $312.2 million as of December 31, 2023 as originations of...

BERKELEY HEIGHTS, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced third quarter financial results and provided a business update. “We were pleased to report initial safety and efficacy data from twelve patients with advanced solid tumors enrolled in the Phase 2 part of the 065-101, proof of concept, clinical study of fadraciclib as a single agent as a poster presentation at the 2024 EORTC-NCI-AACR 36th Symposium on Molecular Targets and Cancer Therapeutics (“Triple Meeting”), in Barcelona, Spain. The patients were enrolled in the biomarker-enriched, Cohort 8 of the study and were preselected for CDKN2A and/or CDKN2B abnormalities,” said Spiro Rombotis,...

Monthly Active Users Reached Approximately 76.9 million for the QuarterRecord Global Net Additions to Paying Circles of 159 thousand – Reaching Nearly 2.2 million TotalTotal Revenue Grew 18% Year-Over-Year to $92.9 million Annualized Monthly Revenue increased 30% Year-Over-Year to $336.2 millionRaising Outlook for 2024 Adjusted EBITDA SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) — San Francisco area-based Life360, Inc. (Life360 or the Company) (NASDAQ: LIF) (ASX: 360) today reported unaudited financial results for the quarter ended September 30, 2024. The Company built on momentum from the previous quarter and again achieved record quarterly results in Monthly Active Users (“MAUs”), Paying Circles, Subscription Revenue, and Annualized Monthly Revenue. “Life360 made tremendous progress in Q3 2024, achieving our best-ever...

BEDFORD, Texas, Nov. 12, 2024 (GLOBE NEWSWIRE) — Legacy Housing Corporation (“Legacy” or the “Company,” NASDAQ: LEGH) today announced its financial results for the third quarter ended September 30, 2024. Financial Highlights Net revenue for the third quarter of 2024 was $44.3 million, a decrease of 11.4% from the third quarter of 2023. Income from operations for the third quarter of 2024 was $15.3 million, a decrease of 19.4% from the third quarter of 2023. Net income for the third quarter of 2024 was $15.8 million, a decrease of 1.8% from the third quarter of 2023. Basic earnings per share for the third quarter of 2024 was $0.65, a decrease of 1.5% from the third quarter of 2023. Book value for the third quarter of 2024 was $479.3 million, an increase of 11.6% from the third quarter of 2023. Book value per share1 for the third...

WINCHESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) — Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the third quarter 2024 and provided a corporate update. As previously announced, the Company retained Lucid Capital Markets, LLC to act as its financial advisor to explore and evaluate strategic options for maximizing shareholder value. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or other strategic transaction involving the Company. The Synlogic Board of Directors has not set a timetable for the conclusion of this review, nor has it made any decisions related to any further actions or potential strategic...